Skip to main content
Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CTXR ISIN · US17322U2078 LEI · 5493005C10W36P4KQP40 US Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country US United States of America
Listing US CTXR

About Citius Pharmaceuticals, Inc.

https://www.citiuspharma.com/

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that develops and commercializes critical care products. The company's diversified pipeline focuses on anti-infectives in adjunct cancer care, stem cell therapies, and prescription products. Its portfolio includes LYMPHIR™, an FDA-approved therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Key product candidates in development include Mino-Lok®, an antibiotic lock solution intended to treat patients with catheter-related bloodstream infections, and Halo-Lido, a topical formulation for the treatment of hemorrhoids. Additionally, the company is advancing a stem cell therapy platform for conditions such as acute respiratory distress syndrome (ARDS).

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 85% confidence The document is a Form 8-K current report filed with the SEC under the Securities Exchange Act of 1934, disclosing an “Other Event” (presentation of clinical data and press release furnished as an exhibit). It does not contain financial statements or detailed financial data, nor does it constitute an earnings release, proxy, dividend notice, or other specific category. As a regulatory announcement/filing that doesn’t fit a more specific type, it falls under the fallback category “Regulatory Filings (RNS).”
2026-06-01 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 85% confidence The document is a Form S-3 registration statement and preliminary prospectus for the resale of shares (issuable upon warrants) by selling stockholders – i.e., it details an offering of securities and associated fundraising/financing activity. This falls under the “Capital/Financing Update” category.
2026-05-22 English
CURRENT REPORT
Regulatory Filings
2026-05-15 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2026
2026-05-15 English
8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 23, 2026, by Citius Pharmaceuticals, Inc. It reports the entry into a material definitive agreement related to a securities purchase agreement and details about a registered direct offering and private placement of common stock and warrants. The document includes descriptions of the terms of the offering, placement agent fees, and related exhibits such as the purchase agreement and warrants. It also includes press releases announcing the entry and closing of the offering. The Form 8-K is a current report used to disclose significant events or corporate changes that shareholders should know about, specifically here about capital raising activities. This fits the category of Capital/Financing Update (CAP) as it provides detailed information on financing activities and capital structure changes. The document is not an annual or quarterly report, audit report, earnings release, or other categories. The length and content confirm it is a full report, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2026-04-24 English
424B5 - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering, describing the terms of a stock and warrant offering, placement agent fees, and related details. It includes detailed offering terms, pricing, and legal disclaimers typical of a capital raising document. There is no financial statement data or management discussion of financial results. The document is not an annual or quarterly report, earnings release, or management report. It is clearly an update on a financing transaction and capital structure change. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or regulatory filing. Confidence is high due to explicit offering details and SEC filing references.
2026-04-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.